EX-12.1
Published on June 26, 2009
Exhibit 12.1
OncoGenex Pharmaceuticals, Inc.
Computation of Ratio of Earnings to Fixed Charges
Computation of Ratio of Earnings to Fixed Charges
| Three | ||||||||||||||||||||||||
| Months | ||||||||||||||||||||||||
| Fiscal Year Ended | Ended | |||||||||||||||||||||||
| December 31, | March 31, | |||||||||||||||||||||||
| (In $000s, except ratio) | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | ||||||||||||||||||
Fixed Charges: |
||||||||||||||||||||||||
Interest expense |
$ | | $ | | $ | | $ | 193 | $ | 319 | $ | | ||||||||||||
Amortized premiums discounts
and capitalized expenses
related to
indebtedness |
1,248 | 1,843 | 2,604 | 2,944 | 1,973 | | ||||||||||||||||||
| $ | 1,248 | $ | 1,843 | $ | 2,604 | $ | 3,137 | $ | 2,292 | $ | | |||||||||||||
Earnings (loss): |
||||||||||||||||||||||||
Net income (loss) before tax
benefit (provision) |
$ | (3,665 | ) | $ | (4,497 | ) | $ | (10,919 | ) | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,419 | ) | ||||||
Add fixed charges |
1,248 | 1,843 | 2,604 | 3,137 | 2,292 | | ||||||||||||||||||
| $ | (2,417 | ) | $ | (2,654 | ) | $ | (8,315 | ) | $ | (4,686 | ) | $ | (8,399 | ) | $ | (2,419 | ) | |||||||
Ratio of earnings to fixed charges |
| | | | | | ||||||||||||||||||
Deficiency of earnings to fixed
charges |
$ | (3,665 | ) | $ | (4,497 | ) | $ | (10,919 | ) | $ | (7,823 | ) | $ | (10,691 | ) | $ | (2,419 | ) | ||||||